Oragenics (NYSEAMERICAN:OGEN) Shares Cross Above Two Hundred Day Moving Average of $2.25

Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Rating) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.25 and traded as high as $3.17. Oragenics shares last traded at $3.15, with a volume of 9,443 shares traded.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Oragenics in a research note on Tuesday, April 25th. They issued a “sell” rating for the company.

Oragenics Stock Up 0.5 %

The stock has a market cap of $6.16 million, a P/E ratio of -24.21 and a beta of 0.19. The company has a 50-day simple moving average of $3.56 and a two-hundred day simple moving average of $2.25.

Institutional Investors Weigh In On Oragenics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OGEN. Renaissance Technologies LLC grew its stake in shares of Oragenics by 24.4% in the fourth quarter. Renaissance Technologies LLC now owns 288,398 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 56,498 shares during the last quarter. Millennium Management LLC grew its stake in shares of Oragenics by 591.6% in the second quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 110,119 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Oragenics by 8.1% in the first quarter. State Street Corp now owns 495,563 shares of the biotechnology company’s stock worth $171,000 after acquiring an additional 37,338 shares during the last quarter. 9.31% of the stock is owned by hedge funds and other institutional investors.

Oragenics Company Profile

(Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.